Evidence map›Paper›PMID 40143124›Full record

ReviewPharmaceuticals (Basel, Switzerland)2025

Glial Modulator Antibiotics for Neuropathic Pain: Current Insights and Future Directions.

Alex J Zimmerman, Nicholas Mangano, Grace Park, Amit K Kaushal, Sergio D Bergese

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alex J ZimmermanDepartment of Physical Medicine and Rehabilitation, Stony Brook Medicine, Stony Brook, NY 11794, USA.
Nicholas ManganoDepartment of Anesthesiology, Stony Brook Medicine, Stony Brook, NY 11794, USA.
Grace ParkRenaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.
Amit K KaushalChronic Pain Division, Department of Anesthesiology, Stony Brook Medicine, Stony Brook, NY 11794, USA.
Sergio D BergeseDepartment of Anesthesiology, Stony Brook Medicine, Stony Brook, NY 11794, USA.ORCID 0000-0001-5641-5908

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pathological pain is defined as pain that outlives its usefulness as a protective warning system and becomes debilitating, disrupting normal life function. Understanding the mechanism of transition from physiological to pathological pain is essential to provide the effective prevention of chronic pain. The main subcategories of pathological pain are nociceptive pain, neuropathic pain, and nociplastic pain. Glial cells play pivotal roles in the development and maintenance of each of these pathological pain states, specifically neuropathic pain. Consequently, targeting these cells has emerged as a promising therapeutic strategy, as limited efficacy and harmful adverse effects are associated with current pharmacotherapies. This paper aims to review specific antibiotics that modulate glial cells, which can be used to treat neuropathic pain. These antibiotics include minocycline, doxycycline, ceftriaxone, and azithromycin. The potential of these antibiotics appears promising, particularly given the extensive prior research and use of these antibiotics in humans for other illnesses. However, each presents its own set of limitations, ultimately making the translation from preclinical findings to human therapies for neuropathic pain challenging.

Indexed as

azithromycinceftriaxonedoxycyclineglialminocyclineneuropathic pain

Identifiers

PMID40143124
PMCPMC11944926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.